Semaglutide Constipation: Causes, How Long It Lasts, and the Best Relief Strategies

Constipation is a predictable effect of semaglutide. Learn why it happens, how long it typically lasts, and the most effective strategies for relief.

Semaglutide Constipation: Causes, How Long It Lasts, and the Best Relief Strategies

Key Takeaways

  • Constipation is a direct pharmacological consequence of semaglutide, not a dietary mistake or a sign the medication is failing.
  • Incidence ranges from approximately 3–5% at diabetes doses to up to 24% at Wegovy's 2.4 mg weight management dose — the higher the dose, the greater the risk.
  • For Wegovy 2.4 mg users, the median duration of constipation was 47 days versus 35 days in the placebo group, with prevalence plateauing at approximately week 10.
  • First-line relief: consistent hydration, gradual fiber increases, daily movement, and structured meals.
  • When lifestyle changes are not enough, osmotic laxatives (polyethylene glycol 3350) are the clinically preferred first-line pharmacological option.
  • For people who want appetite control without the GI side effect burden, natural GLP-1 stimulation via Amarasate® works through a mechanism that does not slow gastric emptying.

Constipation is one of the most commonly reported side effects of semaglutide — and one of the least openly discussed. Most people starting Ozempic® or Wegovy® hear about nausea. Fewer are prepared for what can happen on the other end.

This is not a sign that the medication isn't working, and it is not a dietary mistake. Constipation on semaglutide is a predictable physiological consequence of how the medication acts on the digestive system. It is manageable, and understanding why it happens is the first step to managing it effectively.

This guide covers why semaglutide causes constipation, what the data says about how common it is and how long it typically lasts, the most effective relief strategies, and what the natural alternatives look like for readers who want appetite control without the gastrointestinal (GI) trade-offs. For more on semaglutide constipation and how GI side effects relate to the decision to stop, our guide to what happens when you stop injectable medications covers the full picture.

Why Does Semaglutide Cause Constipation?

Semaglutide activates GLP-1 (glucagon-like peptide-1) receptors distributed throughout the GI tract, significantly slowing gastric emptying and small intestine transit time. Slower transit means food and waste spend more time in the colon, where water is progressively absorbed — producing harder, drier stools.1

There is a compounding factor. Semaglutide's appetite suppression reduces overall food and fluid intake. People eat less, drink less, consume less fiber, and generate less gut motility stimuli. All of these inputs normally keep the digestive system moving. When they decrease simultaneously, the effect on transit is amplified.

That slowing is also why constipation on semaglutide catches so many people off guard — it is a direct consequence of how the medication works, not a sign that something has gone wrong.

How Common Is Constipation on Semaglutide?

Constipation affects a significantly different proportion of people depending on which semaglutide formulation they are taking and at what dose. Most competitor articles conflate these figures — the distinction matters if you are trying to understand what to expect.

Constipation Rates by Formulation and Dose

Formulation Dose / Indication Constipation Incidence (%)
Ozempic® (injection)2 0.5 mg / Type 2 diabetes 5%
Wegovy (injection)3 2.4 mg / weight management 24%
Rybelsus® (oral)4 7 mg / Type 2 diabetes 6%
Wegovy (oral)5 25 mg / weight management 20%
Zepbound (injection)6 10 mg / weight management 14%

The dose is the primary driver of incidence. People on Wegovy 2.4 mg for weight management face a substantially higher rate than those on lower Ozempic doses for Type 2 diabetes.7,8

Also important: constipation from semaglutide tends to persist longer than nausea and is often less discussed, despite being just as disruptive over weeks of treatment. In fact, in the pivotal 68-week semaglutide studies, the median duration constipation varied between 42 and 47 days, although around 7-10% of participants experienced it for the entire time.9

A Counterintuitive Finding Worth Knowing

A May 2026 retrospective analysis presented at Digestive Disease Week by Thomas Fredrick, MD., of the Mayo Clinic, found that participants on semaglutide who experienced constipation had 14.4% total body weight loss at 12 months, compared to 10.8% in those without constipation.10

Constipation was associated with higher doses and lower rates of Type 2 diabetes — the population most likely reading this article.

This finding should be interpreted carefully. As Fredrick himself acknowledged, it is hypothesis-generating, not established causation. It does not mean constipation is desirable. What it may offer a reader who feels like something is going wrong is a reframe: constipation at higher semaglutide doses may be a signal that the medication is working at the level that produces results.

It's also important to note that the STEP trials of semaglutide in weight management showed no differences in weight loss between those who experienced GI side effects (which amounted to a quarter of the semaglutide group).11

How Long Does Semaglutide Constipation Last?

For people on Wegovy 2.4 mg, the median duration of constipation was 47 days, compared to 35 days in the placebo group, with prevalence plateauing at approximately week 10.12 That plateau is meaningful: for most people, constipation does not continue to worsen indefinitely as the drug accumulates.

Many people resolve symptoms within 2 to 3 weeks once dietary adjustments are made and the body adapts to the initial titration phase. Constipation tends to peak during dose escalation; each new dose increment is when symptoms are most likely to worsen or return.

For up to 10% of people, constipation persists throughout treatment at the higher maintenance dose.13 This is where sustained dietary and lifestyle management, and where necessary, ongoing OTC support, becomes part of the long-term routine.

The Best Relief Strategies for Semaglutide Constipation

Most cases respond well to a combination of dietary, lifestyle, and, where necessary, pharmacological interventions. The goal is to work with the medication, not against it.

Hydration

Semaglutide's appetite suppression often reduces unconscious fluid intake; people drink less because they eat less and feel less thirsty. What's more, these medication types also act centrally in the brain to reduce thirst.14 Try to keep up your water intake, regardless, though avoid drinking excessively during meals and don't use a straw to drink.15

A practical tip: a large glass of water first thing in the morning, before food, stimulates the "gastrocolic reflex" and can prompt a bowel movement. Electrolyte drinks — coconut water, oral rehydration solutions — can help if nausea is making plain water unappealing. (Note that if you're taking the Wegovy pill, you need to wait at least 30 minutes from taking it before you drink a large glass of water.)

Fiber — Gradual Increases, Not Sudden Ones

It's very important to maintain adequate dietary fiber if you're constipated (but to limit it if you're experiencing diarrhea).16 However, increasing fiber too quickly when already constipated can worsen bloating and discomfort, so aim to gradually up your daily fiber intake. Soluble fiber is particularly effective — oats, legumes, chia seeds, and psyllium husk absorb water, soften stool, and feed gut bacteria that support motility. If eating significantly less on semaglutide, prioritize fiber-dense foods at every meal: vegetables, legumes, and fruit with skin. For a guide on fiber-rich foods, see this Mayo Clinic chart.

Movement

Physical activity stimulates intestinal contractions and speeds gut transit time — one of the most clinically supported non-pharmacological interventions for constipation.17 Twenty to thirty minutes of daily walking has a meaningful impact on gut motility; consistency matters more than intensity.

Meal Structure

Eating regular meals at consistent times supports the body's natural motility rhythms. Irregular eating or skipping meals due to low appetite disrupts this. Warm liquids in the morning — water, herbal tea — help stimulate gut motility. Small, structured meals are better for gut function than prolonged fasting during the day, even when appetite is very low.18

Over-the-Counter Options

If dietary and lifestyle adjustments do not resolve constipation within 1 to 2 weeks, OTC options are appropriate:

  • Osmotic laxatives (polyethylene glycol 3350 /MiraLax®): recommended by gastroenterologists for semaglutide-related constipation, they draw water into the colon to soften stool; gentle, non-habit-forming; safe for extended use.19
  • Stool softeners (docusate sodium): may be useful for mild constipation, although docusate is widely used as a laxative, its clinical effectiveness remains unproven and it's not FDA-approved for the treatment of constipation.20 Users may become dependent on docusate.
  • Stimulant laxatives (senna, bisacodyl): senna has better evidence in support of its use for (general) chronic constipation than bisacodyl, but neither has been specifically recommended for treating GLP-1 constipation.21 Stimulant laxatives should be reserved for short-term or rescue use only.
  • Psyllium husk: a soluble fiber supplement that works as a gentle osmotic agent; it requires adequate hydration to work safely. Psyllium is the most effective fiber supplement for treating chronic constipation.22

Always consult a prescribing doctor before adding regular OTC laxatives alongside semaglutide, particularly for those managing Type 2 diabetes.

Natural GLP-1 Support Without the Digestive Side Effects

GI side effects are among the leading reasons people discontinue GLP-1 medications, and constipation, while likely less distressing than nausea or vomiting, accumulates as a quality-of-life issue over weeks and months.

The mechanism that causes constipation is inseparable from pharmaceutical-strength GLP-1 receptor activation. Flooding GLP-1 receptors throughout the body slows gastric emptying along the entire GI tract. The GI disruption is not a flaw in the design — it is the design, operating at pharmacological doses.

Natural GLP-1 stimulation works differently. Increasing your body's levels of its natural GLP-1 can help manage your appetite without the body-wide receptor activation that drives GIslowdown at pharmacological doses. The appetite signal is real. The mechanism is different.

Amarasate, the active ingredient in Calocurb®, does exactly this, by stimulating bitter taste receptors on specialized "enteroendocrine L-cells" throughout the gut, which then triggers local release of the body's own GLP-1 (and other "stop eating" hormones, CCK and PYY). Three peer-reviewed, published human clinical trials show:

~18%

Reduction in caloric intake at a subsequent meal, with measurable increases in GLP-1 and other satiety hormones (640% for GLP-1, 600% for CCK, and 170% for PYY over baseline)23

Significant

Hunger reduction in men during a 24-hour fast24

30%

Hunger reduction, 40% reduction in food cravings, and 14% fewer calories consumed in women during a 24-hour fast25

No statistically significant adverse effects were reported across the three trials. Effects on appetite were measurable within one hour of dosing. Amarasate is not a replacement for people who clinically need pharmaceutical GLP-1 management. It is the evidence-backed option for people who want appetite control without the GI trade-offs — or who are transitioning off semaglutide and want to maintain results. It's also been used alongside GLP-1s to allow for a reduced dose of the medication and a reduction in their side effects. For more on why appetite support matters post-GLP-1, our guide covers the transition in detail.

Learn more at Calocurb's science page or explore the product.

Natural appetite control

Support appetite without the GI side effects

Calocurb® activates your body's natural GLP-1 without slowing gastric emptying. Three peer-reviewed clinical trials show meaningful appetite reduction and satiety hormone increases — with no statistically significant adverse effects.

Shop now Learn more
Calocurb bottle

Frequently Asked Questions

Does semaglutide cause constipation?
Yes. Constipation is a direct pharmacological effect of semaglutide. The medication activates GLP-1 receptors throughout the GI tract, slowing gastric emptying and intestinal transit. Incidence ranges from approximately 4–6% at diabetes doses to up to 20–24% at Wegovy's oral and injectable weight management doses.
How long does constipation last on semaglutide?
In the pivotal semaglutide weight loss trials at 2.4 mg, the median duration was 42–47 days, with prevalence plateauing at approximately week 10 in clinical trial data. Many people see improvement within 2 to 3 weeks once dietary adjustments are made. Constipation may return or worsen with each dose escalation.
How do you relieve constipation from Ozempic?
Start with hydration (8 to 10 cups of water daily), adequate dietary fiber intake, and 20 to 30 minutes of daily walking. If lifestyle measures don't resolve symptoms within 1 to 2 weeks, consider an osmotic laxative like MiraLax. A soluble fiber supplement containing psyllium husk can also be used.
Is constipation worse on Wegovy than Ozempic?
Yes, based on prescribing data and trial results. Constipation incidence at Wegovy's 2.4 mg weight management dose reaches up to 24% in clinical trials, compared to 5% at Ozempic's 0.5 mg diabetes dose. The dose is the primary driver of incidence.
Does constipation from semaglutide go away on its own?
For many people, constipation improves as the body adapts, particularly after the dose escalation phase stabilizes. In clinical trial data for Wegovy 2.4 mg, constipation prevalence plateaued at approximately week 10. Active dietary management — not passive waiting — is the most reliable path to resolution.
What is the best laxative to take with Ozempic?
Polyethylene glycol 3350 (MiraLax) is recommended as the first-line option for semaglutide-related constipation. It is gentle, non-habit-forming, and safe for extended use (up to 6 months in adults). Stimulant laxatives should be reserved for short-term or rescue use only.
Can you prevent constipation while taking semaglutide?
Prevention is possible with proactive management. Start hydration and gradual fiber increases before constipation develops. Maintain regular meal timing, incorporate daily movement, and limit alcohol. Beginning these habits at the start of treatment — rather than waiting for symptoms — is significantly more effective.
When should I be worried about constipation on Ozempic?
Seek medical attention if you have no bowel movement for more than 5 days, experience severe abdominal pain, see blood in the stool, have persistent vomiting alongside constipation, or suspect fecal impaction. These situations require clinical evaluation, not home management.
Does constipation mean semaglutide is working?
A 2026 retrospective analysis presented at Digestive Disease Week found that semaglutide users who experienced constipation lost more weight at 12 months (14.4% vs. 10.8%) than those without it. Constipation is not a necessary or desirable sign of efficacy, but it may reflect higher doses that produce stronger appetite suppression.

References

  1. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530. doi:10.1155/2011/279530
  2. Ozempic. Prescribing information. Novo Nordisk Inc.; May, 2026. Accessed Jun 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf
  3. Wegovy Prescribing information. Novo Nordisk Inc.; June, 2026. Accessed Jun 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
  4. Rybelsus. Prescribing information. Novo Nordisk Inc.; January, 2026. Accessed Jun 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
  5. Wegovy Prescribing information. Novo Nordisk Inc.; June, 2026. Accessed Jun 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
  6. Zepbound. Prescribing information. Lilly; February, 2026. Accessed Jun 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
  7. Ozempic. Prescribing information. Novo Nordisk Inc.; May, 2026. Accessed Jun 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf
  8. Wegovy Prescribing information. Novo Nordisk Inc.; June, 2026. Accessed Jun 25, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
  9. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2021;24(1). doi:10.1111/dom.14551
  10. Larkin M. Constipation linked to greater weight loss on semaglutide. Medscape. Published May 4, 2026. Accessed Jun 26, 2026. https://www.medscape.com/viewarticle/constipation-linked-greater-weight-loss-semaglutide-2026a1000e66
  11. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2021;24(1). doi:10.1111/dom.14551
  12. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2021;24(1). doi:10.1111/dom.14551
  13. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2021;24(1). doi:10.1111/dom.14551
  14. McKay NJ, Kanoski SE, Hayes MR, Daniels D. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake. Am J Physiol Regul Integr Comp Physiol. 2011;301(6):R1755-R1764. doi:10.1152/ajpregu.00472.2011
  15. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145. Published 2022 Dec 24. doi:10.3390/jcm12010145
  16. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145. Published 2022 Dec 24. doi:10.3390/jcm12010145
  17. Severo JS, Silva ACAD, Santos BLBD, et al. Physical exercise as a therapeutic approach in gastrointestinal diseases. J Clin Med. 2025;14(5):1708. Published 2025 Mar 3. doi:10.3390/jcm14051708
  18. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145. Published 2022 Dec 24. doi:10.3390/jcm12010145
  19. Schoenfeld P. Continued treatment with tirzepatide is necessary to maintain weight loss. American College of Gastroenterology. Published February 20, 2024. Accessed Jun 26, 2026. https://gi.org/journals-publications/ebgi/schoenfeld2_feb2024/
  20. Hannoodee S, Patel P, Annamaraju P. StatPearls: docusate. PubMed. Published August 17, 2023. Accessed Jun 26, 2026. https://www.ncbi.nlm.nih.gov/books/NBK555942/
  21. Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol. 2021;116(6):1156-1181. doi:10.14309/ajg.0000000000001222
  22. ‌van der Schoot A, Drysdale C, Whelan K, Dimidi E. The effect of fiber supplementation on chronic constipation in adults: an updated systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2022;116(4):953-969. doi:10.1093/ajcn/nqac184
  23. Walker EG, Lo KR, Pahl MC, et al. An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. Am J Clin Nutr. 2022;115(3):925-940. doi:10.1093/ajcn/nqab418
  24. Walker EG, Lo KR, Tham S, et al. New Zealand bitter hops extract reduces hunger during a 24 h water only fast. Nutrients. 2019;11(11):2754. doi:10.3390/nu11112754
  25. Walker E, Lo K, Gopal P. Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obes Pillars. 2024;11:100117. doi:10.1016/j.obpill.2024.100117
Calocurb

Written by

Calocurb

← Back to blog